IBA Molecular North America, Inc. (IBA Molecular) and MIM Software Inc. (MIM Software™) have announced an agreement to co-develop enhancements to the IBA Molecular PETLinQ™ suite of products

PETNET Solutions, a wholly owned subsidiary of Siemens Medical Solutions USA, Inc., will soon begin manufacturing Eli Lilly and Company’s AmyvidTM (Florbetapir (18F)) radiopharmaceutical in the United Kingdom, as well as in Spain and France, after signing a manufacturing services agreement with Eli Lilly and Company. Siemens’ PETNET Solutions will function as a contract manufacturer for Lilly after Lilly’s diagnostic radiopharmaceutical received marketing authorisation from the European Commission in early 2013.

IBA (Ion Beam Applications S.A.), the global high-tech leader in next generation radiation therapy and diagnostics for the treatment of cancer, is pleased to announce that today 60 radiation therapy leaders travelled to Belgium to discover the first Proteus®ONE in factory.

UltraSPECT, a leading provider of nuclear medicine (NM) image reconstruction technology that reduces radiopharmaceutical dose and acquisition time, announces today the installation of its proprietary Wide Beam Reconstruction (WBR™) software at nearly ten healthcare facilities.

A team of radiologists and neurologists at University Hospitals Case Medical Center in Cleveland are enrolling patients with suspected early-stage Alzheimer’s disease in a study designed to determine if Amyvid can identify amyloid plaques via PET or MRI. Read more about the research by clicking the link below.

Baxter announced results of its Phase III clinical study of immunoglobulin (IG). In the randomized, double-blind, placebo-controlled, multi-center trial, IG did not meet its co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer's disease after 18 months of treatment. Given the findings, Baxter said it will re-evaluate its approach for its Alzheimer’s program.

MILabs, B.V. the Netherlands‐based innovator and manufacturer of pre‐clinical SPECT/PET/CT imaging devices used in biomedical research, today announces the release of the new mini product family ‐ an easy‐to‐use series of benchtop SPECT and PET imagers for small animals that combine simplified workflow, compact dimensions and affordable pricing to bring high‐performance SPECT/PET within everyone’s reach.

Navidea Biopharmaceuticals, Inc. (NYSE MKT:  NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostic radiopharmaceuticals, today announced the U.S. launch of Lymphoseek® (technetium Tc 99m tilmanocept) Injection for use in lymphatic mapping procedures that are performed to help in the diagnostic evaluation of potential cancer spread for patients with breast cancer and melanoma.